##semicolon##
epilepsy, comorbidity, age groups, cardiovascular diseases, endocrine disorders, gastrointestinal disturbances##submission.citations##
World Health Organization. Epilepsy: a public health imperative. Geneva: WHO Press; 2019. 144 p.
Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol. 2016;15(1):106-115.
Gaitatzis A, Carroll K, Majeed A, Sander JW. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia. 2004;45(12):1613-1622.
Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007;48(12):2336-2344.
Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol. 2016;12(2):106-116.
Pugh MJ, Knoefel JE, Mortensen EM, et al. New-onset epilepsy risk factors in older adults: development of an informative literature. Biomed Res Int. 2014;2014:120858.
Josephson CB, Jetté N. Psychiatric comorbidities in epilepsy. Int Rev Psychiatry. 2017;29(5):409-424.
Bardai A, Lamberts RJ, Blom MT, et al. Epilepsy is a risk factor for sudden cardiac arrest in the general population. PLoS One. 2012;7(8):e42749.
Tomson T, Nashef L, Ryvlin P. Sudden unexpected death in epilepsy: current knowledge and future directions. Lancet Neurol. 2008;7(11):1021-1031.
Verrotti A, Scaparrotta A, Grosso S, et al. Anticonvulsant drugs and precocious puberty: a possible association. Eur J Pediatr. 2014;173(6):715-720.
Morrell MJ, Hayes FJ, Sluss PM, et al. Hyperinsulinemia, ovarian dysfunction, and altered bone densitometry in valproate-treated women with epilepsy. Ann Neurol. 2008;64(2):200-211.
Sheth RD, Wesolowski CA, Jacob JT, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr. 1995;127(2):256-262.
Guo Y, Ding MP, Shen CH, et al. Hyperammonemia due to valproate: a single center experience. Int J Med Sci. 2019;16(8):1072-1077.
Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology. 2016;63(2):590-603.
Karimov J, Ibragimov O. Epilepsy management in Central Asia: current challenges and perspectives. Epilepsy Res. 2021; 175:106691.
Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy. Epilepsia. 2017;58(4):522-530.
Keezer MR, Bell GS, Neligan A, Novy J, Sander JW. Cause of death and predictors of mortality in a community-based cohort of people with epilepsy. Neurology. 2016;86(8):704-712.
Stollberger C, Finsterer J. Cardiorespiratory findings in sudden unexplained/ unexpected death in epilepsy (SUDEP). Epilepsy Res. 2004;59(1):51-60.
Mintzer S, Skidmore CT, Abidin CJ, et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol. 2009;65(4):448-456.
Verrotti A, Manco R, Agostinelli S, et al. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia. 2010;51(2):268-273.
Pylvänen V, Pakarinen A, Knip M, Isojärvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav. 2006;8(3):643-648.
Pack AM, Morrell MJ, Randall A, et al. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology. 2008;70(18):1586-1593.
Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71(12):1565-1575.
Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246-255.